DK0553178T3 - Bifasiske afgivelsesformuleringer til lipofile lægemidler - Google Patents

Bifasiske afgivelsesformuleringer til lipofile lægemidler

Info

Publication number
DK0553178T3
DK0553178T3 DK91918238.6T DK91918238T DK0553178T3 DK 0553178 T3 DK0553178 T3 DK 0553178T3 DK 91918238 T DK91918238 T DK 91918238T DK 0553178 T3 DK0553178 T3 DK 0553178T3
Authority
DK
Denmark
Prior art keywords
pct
active substance
fatty acid
date
pharmaceutically active
Prior art date
Application number
DK91918238.6T
Other languages
English (en)
Inventor
Stephen George Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Application granted granted Critical
Publication of DK0553178T3 publication Critical patent/DK0553178T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Laminated Bodies (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK91918238.6T 1990-10-19 1991-10-18 Bifasiske afgivelsesformuleringer til lipofile lægemidler DK0553178T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
DK0553178T3 true DK0553178T3 (da) 1995-07-24

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91918238.6T DK0553178T3 (da) 1990-10-19 1991-10-18 Bifasiske afgivelsesformuleringer til lipofile lægemidler

Country Status (21)

Country Link
US (1) US5391377A (da)
EP (1) EP0553178B1 (da)
JP (1) JP3276368B2 (da)
KR (1) KR100188642B1 (da)
AT (1) ATE122881T1 (da)
AU (1) AU656924B2 (da)
BG (1) BG61383B1 (da)
CA (1) CA2093206C (da)
CZ (1) CZ282822B6 (da)
DE (1) DE69110052T2 (da)
DK (1) DK0553178T3 (da)
ES (1) ES2073177T3 (da)
FI (1) FI104408B (da)
GB (1) GB9022788D0 (da)
HK (1) HK85296A (da)
HU (2) HUT64215A (da)
NO (1) NO305505B1 (da)
RO (1) RO114739B1 (da)
RU (1) RU2121344C1 (da)
SK (1) SK279845B6 (da)
WO (1) WO1992006680A1 (da)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773025A (en) 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
EP0808154B1 (en) * 1995-02-06 2000-12-20 Elan Pharma International Limited Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
CA2224227A1 (en) * 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
IL123505A (en) 1996-07-08 2004-12-15 Penwest Pharmaceuticals Compan Sustained release matrix for high-dose insoluble drugs
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
IN186245B (da) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
US7163705B2 (en) 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
US7115288B2 (en) 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
RU2217138C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-2" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
US20040248850A1 (en) * 2003-02-11 2004-12-09 Kemia, Inc. Compounds for the treatment of HIV infection
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
AU2005204391A1 (en) * 2004-01-14 2005-07-28 Lavipharm Laboratories, Inc. Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
MXPA06009054A (es) * 2004-02-11 2007-04-16 Athpharma Ltd Composiciones cronoterapeuticas y metodos de su uso.
CA2566549C (en) 2004-05-12 2014-01-14 The Walter And Eliza Hall Institute Of Medical Research A method for isolating mammary stem cells
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
US8119601B2 (en) * 2005-03-10 2012-02-21 Ben-Gurion University Of The Negev Research And Development Authority Ltd. Voltage dependent anion channel (VDAC1) compositions and methods of use thereof for regulating apoptosis
KR20080007491A (ko) 2005-04-29 2008-01-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
DK2407484T3 (da) 2005-06-24 2016-09-05 The Walter And Eliza Hall Inst Of Medical Res Terapeutisk pro-apoptotisk BH3-lignende molekyler og fremgangsmåder til at generere og/eller udvælge disse
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
EP1991274A4 (en) 2006-01-20 2009-06-10 Women S And Children S Health METHOD OF TREATMENT, PROPHYLAXIS AND DIAGNOSIS OF BONE PATHOLOGIES
EP2004680B1 (en) * 2006-04-06 2017-06-21 Ben-Gurion University Of The Negev N-terminal vdac variants and uses thereof
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
KR101390695B1 (ko) * 2006-08-01 2014-04-30 오츠카 세이야쿠 가부시키가이샤 약리 활성 물질의 흡수성이 개선된 의약 조성물
EP2086512A2 (en) * 2006-10-27 2009-08-12 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
JP2010530895A (ja) * 2007-06-21 2010-09-16 アンジェリカ セラピューティックス，インク． 修飾毒素
CA2693310C (en) 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA3027974C (en) * 2007-10-03 2022-03-15 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
EP2268297A4 (en) * 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
KR101235951B1 (ko) * 2008-05-12 2013-02-21 화이자 인코포레이티드 통기구를 구비한 개선된 캡슐
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EA025367B1 (ru) 2009-08-17 2016-12-30 Тракон Фармасьютикалз, Инк. Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf
US8221753B2 (en) * 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
KR101930179B1 (ko) 2010-08-27 2018-12-17 길리아드 바이오로직스, 인크. 매트릭스 메탈로프로테이나제 ９에 대한 항체
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
CA2834657A1 (en) 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
CN103957888B (zh) * 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
TWI787670B (zh) 2011-12-28 2022-12-21 日商中外製藥股份有限公司 具有環狀部之胜肽化合物及其醫藥組成物
AU2012318302C1 (en) 2012-02-29 2017-06-15 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
NZ629178A (en) 2012-02-29 2016-09-30 Gilead Biologics Inc Antibodies to matrix metalloproteinase 9
CN104203263A (zh) 2012-03-01 2014-12-10 耶达研究与发展有限公司 利用HSP60衍生肽再生胰岛β细胞
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
JP2015524397A (ja) 2012-07-20 2015-08-24 ラトローブ ユニヴァーシティ 診断及び処置の方法
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
EP2996706B1 (en) 2013-03-14 2019-07-31 UAB Research Foundation Apolipoprotein mimetics and uses thereof
EP2968450A4 (en) 2013-03-15 2016-10-26 Angelica Therapeutics Inc MODIFIED TOXINS
US10017551B2 (en) 2013-03-15 2018-07-10 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
US9657098B2 (en) 2013-03-15 2017-05-23 Intrinsic Lifesciences, Llc Anti-hepcidin antibodies and uses thereof
EP3024844B1 (en) 2013-07-25 2018-09-12 The National Institute for Biotechnology in the Negev Ltd. Short peptides derived from vdac1, compositions and methods of use thereof
CN105873944A (zh) 2013-12-20 2016-08-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 促血管发生的肽和肽缀合物
EA201691414A1 (ru) 2014-02-27 2017-03-31 Джилид Сайэнс, Инк. Антитела к матриксной металлопротеиназе 9 и способы их применения
EA201692202A1 (ru) 2014-06-11 2017-06-30 Джилид Сайэнс, Инк. Способы лечения сердечно-сосудистых заболеваний
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
CN106661088B (zh) 2014-07-17 2024-06-21 耶路撒冷希伯来大学伊萨姆研究发展有限公司 鱼类繁殖中的神经激肽b拮抗剂
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
AU2015321462B2 (en) 2014-09-22 2020-04-30 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
EP3368551B1 (en) 2015-10-27 2023-07-12 The University Of Queensland A modified epha4 polypeptide
WO2017083700A1 (en) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
AU2017248354A1 (en) 2016-04-08 2018-10-04 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
EP4039250A1 (en) * 2016-12-28 2022-08-10 Chugai Seiyaku Kabushiki Kaisha Self-emulsifying drug formulation for improving membrane permeability of compound
US11590203B2 (en) 2017-01-30 2023-02-28 Hudson Institute of Medical Research Method of treatment ovarian cancer
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
US11655307B2 (en) 2017-05-30 2023-05-23 The Board Of Regents Of The University Of Oklahoma Anti-doublecortin-like kinase 1 antibodies and methods of use
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN112888707B (zh) 2018-08-16 2025-04-25 百欧恩泰美国公司 T细胞受体构建体及其用途
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
MX2021015411A (es) 2019-06-11 2022-04-18 Myeloid Therapeutics Inc Composiciones acopladoras especificas de macrofagos y metodos de uso de las mismas.
CA3141084A1 (en) 2019-06-12 2020-12-17 Vikram JUNEJA Neoantigen compositions and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
US20230374455A1 (en) 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof
CN120359048A (zh) 2022-09-02 2025-07-22 美洛德生物医药公司 用于细胞特异性表达的组合物及其用途
WO2024233456A1 (en) 2023-05-05 2024-11-14 The Board Of Regents Of The University Of Oklahoma Variants of adrenomedullin (am) and adrenomedullin 2/intermedin (am2/imd) and methods of use
WO2025042868A1 (en) 2023-08-23 2025-02-27 The Board Of Regents Of The University Of Oklahoma Combinations of heteroarotinoids and glycolytic inhibitors for use as cancer treatments
WO2025059113A1 (en) 2023-09-12 2025-03-20 The Board Of Regents Of The University Of Oklahoma Treatments for enhancing immune response to clostridioides difficile infections
WO2025085360A1 (en) 2023-10-16 2025-04-24 The Board Of Regents Of The University Of Oklahoma Heteroarotinoids and/or cdk4/6 inhibitors for treating human papillomavirus (hpv)-induced dysplasias, warts, and cancer in hpv-infected subjects
WO2025169146A1 (en) 2024-02-09 2025-08-14 Kiniksa Pharmaceuticals, Gmbh Cd40 antagonist or cd154 antagonist for use in mitigating immune responses in protein and gene therapies
WO2025219955A1 (en) 2024-04-17 2025-10-23 BioNTech SE Soluble tcrs and methods of use thereof
WO2025224684A1 (en) 2024-04-24 2025-10-30 BioNTech SE Compositions and methods for producing engineered immune cells
WO2025229503A1 (en) 2024-04-29 2025-11-06 BioNTech SE Methods for identifying exhausted t cells and t-cell receptors thereof
WO2026013643A1 (en) 2024-07-12 2026-01-15 BioNTech SE Methods and compositions for designing epitope strings with linkers
WO2026047601A1 (en) 2024-08-28 2026-03-05 BioNTech SE T-cell receptors (tcrs)
WO2026058153A2 (en) 2024-09-10 2026-03-19 BioNTech SE Hpv-16 t cell receptor uses and compositions thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
DE69110052D1 (de) 1995-06-29
AU8731591A (en) 1992-05-20
KR930701989A (ko) 1993-09-08
BG97644A (bg) 1994-04-29
HK85296A (en) 1996-05-24
GB9022788D0 (en) 1990-12-05
EP0553178A1 (en) 1993-08-04
NO305505B1 (no) 1999-06-14
FI931745A0 (fi) 1993-04-16
CA2093206C (en) 2002-01-29
FI931745L (fi) 1993-04-16
HU9301121D0 (en) 1993-07-28
HU211617A9 (en) 1995-12-28
KR100188642B1 (ko) 1999-06-01
FI104408B (fi) 2000-01-31
ATE122881T1 (de) 1995-06-15
NO931410D0 (no) 1993-04-16
US5391377A (en) 1995-02-21
JPH06502143A (ja) 1994-03-10
WO1992006680A1 (en) 1992-04-30
SK279845B6 (sk) 1999-04-13
NO931410L (no) 1993-04-16
RU2121344C1 (ru) 1998-11-10
DE69110052T2 (de) 1995-10-05
CZ282822B6 (cs) 1997-10-15
HUT64215A (en) 1993-12-28
SK36393A3 (en) 1993-07-07
CA2093206A1 (en) 1992-04-20
AU656924B2 (en) 1995-02-23
RO114739B1 (ro) 1999-07-30
BG61383B1 (en) 1997-07-31
JP3276368B2 (ja) 2002-04-22
CZ64193A3 (en) 1994-01-19
EP0553178B1 (en) 1995-05-24
ES2073177T3 (es) 1995-08-01

Similar Documents

Publication Publication Date Title
DK0553178T3 (da) Bifasiske afgivelsesformuleringer til lipofile lægemidler
RU93048157A (ru) Фармацевтическая композиция двухфазного действия с высвобождением для липофильных лекарственных препаратов, способ ее получения, применение композиции для лечения заболеваний
AR012854A1 (es) Una composicion de suministro de droga para la liberacion controlada de un ingrediente activo en el ambiente estomacal por un periodo de tiempoprolongado, una composicion farmaceutica que la comprende, el uso de dicha composicion en la fabricacion de un medicamento, un proceso para la preparacion
JP2009515910A5 (da)
US20120149779A1 (en) High concentration local anesthetic formulations
JP4624673B2 (ja) 化合物の経皮輸送
DK1341527T3 (da) Farmaceutisk præparat omfattende et aktivstof dispergeret på en matrix
DE60024429D1 (de) Orale pharmazeutische zusammensetzungen, die langkettige triglyceride und lipophile tenside enthalten
DK1189620T3 (da) Formulering indeholdende testosteronundecanoat og amerikansk olie
JPWO1999045934A1 (ja) 発泡性腸溶製剤
NO174412C (no) Fremgangsmåte for fremstilling av en farmasöytisk formulering med programmert frigjöring for oral anvendelse
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
US20100016436A1 (en) Transdermal Administration of Active Agents, in Particular Diclofenac
EP1575555B1 (en) Formulations of finasteride
PARKER Efficacy of nitroglycerin patches: fact or fancy?
JPS5576816A (en) Drug for medicinal fatty liver
CN100413490C (zh) 难溶性药物透皮吸收制剂及其制备工艺
DE69803772D1 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
JP2002520269A5 (da)
DE59908258D1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
GEP20063804B (en) Once-a-day oxycodone formulations
KR970069034A (ko) 술린닥을 활성성분으로 함유하는 소염진통제의 서방성 제제
UA86516C2 (ru) Ветеринарная биологически активная добавка липосомальной формы и способ репаративной терапии в гепатологии
GB2394415A (en) Buccal tablet